Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Deffered Revenue: 2012-2020

Historic Non-Current Deffered Revenue for Ptc Therapeutics (PTCT) over the last 3 years, with Mar 2020 value amounting to $1.8 million.

  • Ptc Therapeutics' Non-Current Deffered Revenue fell 80.03% to $1.8 million in Q1 2020 from the same period last year, while for Mar 2020 it was $1.8 million, marking a year-over-year decrease of 80.03%. This contributed to the annual value of $3.4 million for FY2019, which is 64.87% down from last year.
  • As of Q1 2020, Ptc Therapeutics' Non-Current Deffered Revenue stood at $1.8 million, which was down 48.23% from $3.4 million recorded in Q4 2019.
  • In the past 5 years, Ptc Therapeutics' Non-Current Deffered Revenue registered a high of $11.2 million during Q3 2018, and its lowest value of $1.6 million during Q4 2016.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $8.9 million (2019), whereas its average is $7.6 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Non-Current Deffered Revenue spiked by 401.20% in 2017, and later crashed by 80.03% in 2020.
  • Over the past 5 years, Ptc Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $1.6 million in 2016, then spiked by 401.20% to $8.0 million in 2017, then grew by 22.23% to $9.7 million in 2018, then plummeted by 64.87% to $3.4 million in 2019, then tumbled by 80.03% to $1.8 million in 2020.
  • Its Non-Current Deffered Revenue was $1.8 million in Q1 2020, compared to $3.4 million in Q4 2019 and $5.5 million in Q3 2019.